IP Library Granted Patent US 7,883,696
Granted Patent B2
US 7,883,696 · App. 12/558,137 · Granted Feb 8, 2011

Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response

Assignee: Aeras Global TB Vaccine Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,883,696
App. No.
12/558,137
Granted
Feb 8, 2011
Kind
B2
Abstract

Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.

Claims (15)

1. A method of increasing the production of one or more gene products of interest in a cell or tissue, comprising the step of

administering to said cell or tissue a genetically engineered bacterium comprising nucleic acid sequences encoding: i) said one or more gene products of interest and ii) one or more factors that inhibit a mammalian type I interferon response,

wherein said nucleic acid sequences encoding said one or more gene products of interest are operably linked to a eukaryotic promoter, and said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a eukaryotic promoter or a prokaryotic promoter,

and wherein said step of administering is carried out under conditions which allow said genetically engineered bacterium to invade said cell or tissue, and which allow said cell or tissue to produce said one or more gene products of interest.

2. The method of claim 1 , wherein said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a eukaryotic promoter.

3. The method of claim 1 , wherein said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a prokaryotic promoter.

4. The method of claim 1 , wherein said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are present on a chromosome of said genetically engineered bacterium.

5. The method of claim 1 , wherein one or both of:

i) said nucleic acid sequences encoding said one or more gene products of interest, and

ii) said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response,

are present on a plasmid.

6. The method of claim 1 , wherein said one or more factors that inhibit a mammalian type I interferon response are of viral origin.

7. The method of claim 1 , wherein said one or more gene products of interest are Mycobacterium tuberculosis antigens.

8. The method of claim 1 , wherein said genetically engineered bacterium is a bacterium selected from the group consisting of Shigella, Listeria, Salmonella , and Bacille Calmette-Guerin (BCG).

9. The method of claim 1 , wherein said one or more passenger genes is a heterologous transgene.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 047219 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 24, 2018
From: AERAS
To: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Reel/Frame 047300/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: AERAS
To: INTERNATIONAL AIDS VACCINES INITIATIVE, INC.
Reel/Frame 047219/0122 →
CHANGE OF NAME Recorded Dec 27, 2016
From: AERAS GLOBAL TB VACCINE FOUNDATION
To: AERAS
Reel/Frame 041303/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2012
From: SADOFF, JERALD C; JAMILUDDIN, MOHAMAD F; ANANTHA, RAVI P; FULKERSON, JOHN F, JR.
To: AERAS GLOBAL TB VACCINE FOUNDATION
Reel/Frame 029177/0657 →
Continuity (2)
Division 11854027 · Sep 12, 2007
Related Publication 20100003219A1 · Jan 7, 2010